

L3 ANSWER 1 OF 1 DGENE (C) 2002 THOMSON DERWENT

Full Text

AN **AAV87374** cDNA DGENE
TI New polynucleotides encoding human secreted proteins - derived from e.g. human blood, kidney, foetal lung, placenta, testes, brain, ovary, pituitary, retina and colon cDNA libraries
IN Agostino M J; Jacobs K; Lavallie E R; McCoy J M; Merberg D; Racie L A; Spaulding V; Treacy M
PA (GEMY) GENETICS INST INC.
PI WO---9845435 A2 19981015 633p
AI 1998WO-US06954 19980410
PRAI 1997US-0835913 19970410
PSL Claim 1; Page 544
DED 27 APR 1999 (first entry)
DT Patent
LA English
OS 1999-070076 [06]
DESC EST clone CB37.
KW Expressed sequence tag; secreted protein; haematopoiesis regulator; tissue growth; activin; inhibin; tumour invasion suppressor; EST; human; chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis; receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
ORGN Homo sapiens.
AB This sequence represents an expressed sequence tag (EST), and is a polynucleotide of the invention. The polynucleotides of the invention are all secreted EST sequences isolated from a variety of human tissue sources. The EST sequences and proteins encoded by them are predicted to have useful biological activities which would make them suitable for treating, preventing or ameliorating medical conditions in humans and animals, although no supporting data is given. Suggested activities include nutritional activity, immune stimulating or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumour invasion suppressor activity, tumour inhibition activity. The EST sequences are also stated to be useful for gene therapy.
NA 76 A; 74 C; 69 G; 57 T; 0 other
SQL 276
SEQ
1 gtcccgcgtaa accggcaggc gatgagaaag gaaaccatca ctaagatgct
51 ctggagtacc cgcaccctgt tgaatatcac caaggagcag gtaccacttg
101 tgggtggagga gtacctggac aatgtcaatg agcatgactg gaagatgcta
151 cgaaaccgta tgatggacat agttcaagat gccactttcg tgtatgccac
201 actgcagact gctcactacc accgagatgc cggcctccct gtctacctgt
251 atgaatttga gcaccacacg ctcgag

L3 ANSWER 1 OF 1 DGENE (C) 2002 THOMSON DERWENT

Full Text

AN **AAV87374** cDNA DGENE
 TI New polynucleotides encoding human secreted proteins - derived from e.g. human blood, kidney, foetal lung, placenta, testes, brain, ovary, pituitary, retina and colon cDNA libraries
 IN Agostino M J; Jacobs K; Lavallie E R; McCoy J M; Merberg D; Racie L A; Spaulding V; Treacy M
 PA (GEMY) GENETICS INST INC.
 PI WO---9845435 A2 19981015 633p
 AI 1998WO-US06954 19980410
 PRAI 1997US-0835913 19970410
 PSL Claim 1; Page 544
 DED 27 APR 1999 (first entry)
 DT Patent
 LA English
 OS 1999-070076 [06]
 DESC EST clone CB37.
 KW Expressed sequence tag; secreted protein; haematopoiesis regulator; tissue growth; activin; inhibin; tumour invasion suppressor; EST; human; chemotaxis; chemokinesis; haemostasis; gene therapy; thrombolysis; receptor; ligand; anti-inflammatory; tumour inhibitor; ds.
 ORGN Homo sapiens.
 AB This sequence represents an expressed sequence tag (EST), and is a polynucleotide of the invention. The polynucleotides of the invention are all secreted EST sequences isolated from a variety of human tissue sources. The EST sequences and proteins encoded by them are predicted to have useful biological activities which would make them suitable for treating, preventing or ameliorating medical conditions in humans and animals, although no supporting data is given. Suggested activities include nutritional activity, immune stimulating or suppressing activity, haematopoiesis regulating activity, tissue growth activity, activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic and thrombolytic activity, receptor/ligand activity, anti-inflammatory activity, cadherin/tumour invasion suppressor activity, tumour inhibition activity. The EST sequences are also stated to be useful for gene therapy.
 NA 76 A; 74 C; 69 G; 57 T; 0 other
 SQL 276
 SEQ

```

1  gtcccgcctaa accggcaggc gatgagaaag gaaaccatca ctaagatgct
51  ctggagtacc cgcacctgt tgaatatcac caaggagcag gtaccacttg
101 tggtggagga gtacctggac aatgtcaatg agcatgactg gaagatgcta
151 cgaaaccgta tgatggacat agttcaagat gccactttcg tgtatgccac
201 actgcagact gtcactacc accgagatgc cggcctccct gtctacctgt
251 atgaatttga gcaccacacg ctcgag

```